DESOXY

DESOXY
Names
	Preferred IUPAC name 2-(3,5-Dimethoxy-4-methylphenyl)ethan-1-amine
	Other names 3,5-Dimethoxy-4-methylphenethylamine
Identifiers
CAS Number	63037-49-0 ;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL127679 ;
ChemSpider	21106289 ;
PubChem CID	44350128;
UNII	424LJJ87HT ;
CompTox Dashboard (EPA)	DTXSID80658381 ;
	InChI InChI=1S/C11H17NO2/c1-8-10(13-2)6-9(4-5-12)7-11(8)14-3/h6-7H,4-5,12H2,1-3H3 Key: LLHRMWHYJGLIEV-UHFFFAOYSA-N ; InChI=1/C11H17NO2/c1-8-10(13-2)6-9(4-5-12)7-11(8)14-3/h6-7H,4-5,12H2,1-3H3 Key: LLHRMWHYJGLIEV-UHFFFAOYAV;
	SMILES Cc1c(cc(cc1OC)CCN)OC;
Properties
Chemical formula	C11H17NO2
Molar mass	195.26 g/mol
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). verify (what is ?) Infobox references

4-Desoxymescaline, or 4-methyl-3,5-dimethoxyphenethylamine, is a mescaline analogue related to other psychedelic phenethylamines. It is commonly referred to as DESOXY. DESOXY was discovered by Alexander Shulgin and published in his book PiHKAL.

Effects

The effects of DESOXY vary significantly from mescaline, despite their chemical similarity.^{[citation needed]}

Dosage

A typical dosage is within the range of 40–120 mg and lasts 6–8 hours.^[1]

Pharmacology

DESOXY acts as a serotonin 5-HT₂ receptor agonist.^[2]

Legality

In 1970 the Controlled Substances Act placed mescaline into Schedule I in the United States. It is similarly controlled in other nations. Depending on whether or not it is intended for human consumption, 4-desoxymescaline could be considered an analogue of mescaline, under the Federal Analogue Act and similar bills in other countries, making it illegal to manufacture, buy, possess, or distribute without a DEA or related license.

DESOXY is also an isomer of 2C-D which makes it a schedule 1 drug in the United States.

References

^ Shulgin, Alexander; Ann Shulgin (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628.
^ Wallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, Bonniwell EM, Hennessey JJ, Bock HA, Anderson EI, Sherwood AM, Morris H, de Klein R, Klein AK, Cuccurazzu B, Gamrat J, Fannana T, Zauhar R, Halberstadt AL, McCorvy JD (December 2023). "Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential". Nat Commun. 14 (1): 8221. doi:10.1038/s41467-023-44016-1. PMC 10724237. PMID 38102107.

External links

Alexander Shulgin, Jacob, P. Structure-Activity Relationships of the Classic Hallucinogens and Their Analogs. NIDA Research Monograph 146 (Hallucinogens: An Update), 1994.

[1] Shulgin, Alexander; Ann Shulgin (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628.

[WallachCaoCalkins2023-2] Wallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, Bonniwell EM, Hennessey JJ, Bock HA, Anderson EI, Sherwood AM, Morris H, de Klein R, Klein AK, Cuccurazzu B, Gamrat J, Fannana T, Zauhar R, Halberstadt AL, McCorvy JD (December 2023). "Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential". Nat Commun. 14 (1): 8221. doi:10.1038/s41467-023-44016-1. PMC 10724237. PMID 38102107.

[1]

[2]